Abstract / Description: 

BACKGROUND
Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels.

METHODS
We conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter). Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-LRx, referred to here as APO(a)-LRx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months. The lipoprotein(a) level was measured with an isoform-independent assay. The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses).

RESULTS
The median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter. Administration of APO(a)-LRx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001). There were no significant differences between any APO(a)-LRx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms. The most common adverse events were injection-site reactions.

CONCLUSIONS
APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782. opens in new tab.)

Collection: 
eCardio Hub Collection
Category: 
General CV
Date: 
2020
Author: 
Sotirios Tsimikas, M.D., Ewa Karwatowska-Prokopczuk, M.D., Ph.D., Ioanna Gouni-Berthold, M.D., Jean-Claude Tardif, M.D., Seth J. Baum, M.D., Elizabeth Steinhagen-Thiessen, M.D., Michael D. Shapiro, D.O., Erik S. Stroes, M.D., Patrick M. Moriarty, M.D., B¯rge G. Nordestgaard, M.D., D.M.Sc., Shuting Xia, M.S., Jonathan Guerriero, M.B.A., Nicholas J. Viney, B.Sc., Louis OíDea, M.B., B.Ch., B.A.O., and Joseph L. Witztum, M.D. for the AKCEA-APO(a)-LRx Study Investigators*